
Chinese biotech company BoomRay Pharmaceuticals develops radiopharmaceuticals for cancer, and it works both halves of the theranostic idea: tracers that show where a tumor is, and radioligand therapies that deliver radiation to it. It is a venture-backed company, and on 22 September 2026 it signed an exclusive global license with Swiss pharma major Novartis (NOVN: VX), the leader in radioligand therapy, for an undisclosed preclinical asset in a deal worth up to $900 million. That puts a price on a pipeline that is still early: a diagnostic in mid-stage development and a therapeutic program cleared for trials in China only in December 2025.
BoomRay is based in Suzhou, in China's Jiangsu province, where it opened a headquarters and R&D center in March 2024. The site houses licensed radiochemistry labs and GMP-grade hot cells, and a radiation safety license lets the company produce the isotopes it works with in house.
BoomRay was established in December 2018. It closed a pre-A round in December 2020 and a Series A led by Sequoia China in September 2022. Its lead tracer, BR-02, was cleared for trials by China's National Medical Products Administration (NMPA) in August 2023 and by the US FDA a month later.
BoomRay works only in oncology, and within it on targets where imaging and treatment can share one molecule. Brain tumors are the diagnostic front: BR-02 is aimed at primary and metastatic brain tumors, and in particular at telling tumor progression from the effects of radiotherapy when an MRI scan is equivocal. On the therapy side the company is going after solid tumors that express fibroblast activation protein (FAP), found in the tissue surrounding many cancers, and Nectin-4. Medullary thyroid carcinoma has become the early proving ground for the FAP program, with surgeons using the imaging agent to find disease.
The pitch is chemistry. Each radioligand is assembled from four parts, an isotope, a targeting ligand, a chelator that holds the isotope and a linker, and BoomRay tunes them to control where the drug goes and how fast it clears. Its signature is what it calls covalent targeted radioligand (CTR) technology. Instead of binding and letting go, CTR-FAPI locks onto its target protein irreversibly through a SuFEx-based chemical warhead. BoomRay says this gives higher tumor uptake and longer retention in the tumor, and describes BRP-010 as the only covalent radiopharmaceutical in clinical development. It handles fluorine-18, gallium-68, lutetium-177 and actinium-225 in house.
BR-02 ([18F]BF3-BPA) is an amino acid PET tracer that targets the LAT1 transporter. It is cleared for trials in China and the USA, and a Phase I study at Zhongshan Hospital, Fudan University, enrolled its first subject in April 2024. The company now lists it in Phase IIb, focused on brain metastases, and plans to develop it as a companion diagnostic for boron neutron capture therapy.
BRP-010 (CTR-FAPI) is the theranostic lead, paired with gallium-68 for imaging and lutetium-177 for treatment. The lutetium form received NMPA clearance in December 2025 for advanced FAP-expressing solid tumors, BoomRay's first therapeutic IND. Most of the human data so far come from investigator-initiated studies at Chinese hospitals rather than company-sponsored trials. One, a Phase III study, is testing CTR-FAPI-guided surgery in newly diagnosed medullary thyroid carcinoma; an early lutetium study in metastatic solid tumors has completed. At the 2025 American Thyroid Association meeting, investigators reported that the gallium-68 tracer outperformed the reference agent FAPI-04 in detecting metastatic medullary thyroid cancer.
BRP-020 is a cyclic peptide aimed at Nectin-4, with gallium, lutetium and actinium versions. It is in investigator-initiated study, IND-enabling work is under way, and preclinical data were shown at AACR 2026. A further undisclosed solid-tumor program sits behind it.
The Novartis license of 22 September 2026 is the company's defining event so far. BoomRay receives an upfront payment of undisclosed size and is eligible for up to $900 million in total, counting development, regulatory and sales milestones, plus royalties on global net sales. Neither side has named the asset's target or indication. BFC Group advised BoomRay. Earlier in 2026 the company presented preclinical BRP-020 data and CTR-FAPI surgical-guidance data at the AACR Annual Meeting in April, and in December 2025 it won Chinese IND clearance for the lutetium form of BRP-010.
Bo Shan, chief executive, is a chemist with a PhD from Aston University and more than 20 years in drug R&D and manufacturing, including senior roles at GE Healthcare, ChemPartner, Ascletis Pharma and Antengene. Zhibo Liu, chief scientific officer, is a professor at Peking University's College of Chemistry and Molecular Engineering, trained in radiopharmaceutical chemistry at the University of British Columbia and the NIH. Aihua Wang, senior vice president of clinical development, previously worked at Parexel, BeOne (formerly BeiGene), Antengene and I-Mab. Maoyi Lei is vice president of early discovery.
Novartis is BoomRay's only disclosed commercial partner, and a telling one: it sells Pluvicto (lutetium Lu 177 vipivotide tetraxetan) and Lutathera (lutetium Lu 177 dotatate). The licensed asset is preclinical and unnamed, so it is unclear which disclosed program, if any, it is. BoomRay says it is open to more out-licensing and co-development deals.
Chinese biotech company BoomRay Pharmaceuticals develops radiopharmaceuticals for cancer, and it works both halves of the theranostic idea: tracers that show where a tumor is, and radioligand therapies that deliver radiation to it. It is a venture-backed company, and on 22 September 2026 it signed an exclusive global license with Swiss pharma major Novartis (NOVN: VX), the leader in radioligand therapy, for an undisclosed preclinical asset in a deal worth up to $900 million.
BR-02 ([18F]BF3-BPA) is an amino acid PET tracer that targets the LAT1 transporter. It is cleared for trials in China and the USA, and a Phase I study at Zhongshan Hospital, Fudan University, enrolled its first subject in April 2024. The company now lists it in Phase IIb, focused on brain metastases, and plans to develop it as a companion diagnostic for boron neutron capture therapy.
The Novartis license of 22 September 2026 is the company's defining event so far. BoomRay receives an upfront payment of undisclosed size and is eligible for up to $900 million in total, counting development, regulatory and sales milestones, plus royalties on global net sales. Neither side has named the asset's target or indication. BFC Group advised BoomRay.
BoomRay works only in oncology, and within it on targets where imaging and treatment can share one molecule. Brain tumors are the diagnostic front: BR-02 is aimed at primary and metastatic brain tumors, and in particular at telling tumor progression from the effects of radiotherapy when an MRI scan is equivocal. On the therapy side the company is going after solid tumors that express fibroblast activation protein (FAP), found in the tissue surrounding many cancers, and Nectin-4.
The pitch is chemistry. Each radioligand is assembled from four parts, an isotope, a targeting ligand, a chelator that holds the isotope and a linker, and BoomRay tunes them to control where the drug goes and how fast it clears. Its signature is what it calls covalent targeted radioligand (CTR) technology. Instead of binding and letting go, CTR-FAPI locks onto its target protein irreversibly through a SuFEx-based chemical warhead.
Bo Shan, chief executive, is a chemist with a PhD from Aston University and more than 20 years in drug R&D and manufacturing, including senior roles at GE Healthcare, ChemPartner, Ascletis Pharma and Antengene. Zhibo Liu, chief scientific officer, is a professor at Peking University's College of Chemistry and Molecular Engineering, trained in radiopharmaceutical chemistry at the University of British Columbia and the NIH.
Novartis is BoomRay's only disclosed commercial partner, and a telling one: it sells Pluvicto (lutetium Lu 177 vipivotide tetraxetan) and Lutathera (lutetium Lu 177 dotatate). The licensed asset is preclinical and unnamed, so it is unclear which disclosed program, if any, it is. BoomRay says it is open to more out-licensing and co-development deals.
| Headless Content Management with Blaze